This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk03: Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TraxAid Health's second quarter 2022 earnings conference call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions. The earnings press release accompanying this conference call was issued at the close of the market today. The quarterly report, which includes additional information regarding the company's results of the operations for the quarter ended June 30, 2022, was filed with the SEC earlier today. On our call today is TraxAid Health's founder, chairman, and chief executive officer, Surin Ajayrapu, and Janet Huffman, its chief financial officer. The replay of this call and webcast will be available for the next 30 days on the company's website under the NASDAQ Meds link. The company's website also includes more supporting industry information. At this time, I'd like to turn the call over to Janet Huffman, the company's chief financial officer. Janet, the floor is yours.
spk04: Thank you, operator, and thank you for joining us today. I'd like to welcome you to our 2022 second quarter financial results conference call. A press release announcing our 2022 second quarter financial results was issued after the close of market today and is posted on our website. We have also furnished such press release to the SEC on form 8K. Statements made on this call and webcast will include forward-looking statements. These statements include, but are not limited to, our outlook for the company and statements that estimate or project future results of operations or the performance of the company. These statements speak only as of the date hereof, and the company assumes no obligation, except as required by law, to revise any forward-looking statements that may be made in today's press release, call, or webcast. These statements do not guarantee future performance and are subject to risks, uncertainties, and assumptions. For information on risks, uncertainties, and assumptions that may cause actual results to differ materially from forward-looking statements, please refer to the press release, the risk factors included in our most recent quarterly report, and our most recent annual report. and other documents we file with the Securities and Exchange Commission. These documents include, but are not limited to, our most recent quarterly report on Form 10-Q and any subsequently filed periodic report or current report on Form 8-K. In addition, during today's call and webcast, we will discuss non-GAAP financial measures, which we believe are useful as supplemental measures of TrexAID's performance. These non-GAAP measures should be considered in addition to and not as a substitute for or in isolation from GAAP results. You can find additional disclosures regarding these non-GAAP measures, including reconciliations with comparable GAAP results at the end of our earnings press release. Unless otherwise stated, all financial comparisons in this call will be to our results for the comparable period of fiscal 2021. During the question and answer portion of today's call, please limit yourself to no more than one question and one follow-up. At this time, I'd like to turn the call over to Saren Ajarapu, the company's Chief Executive Officer. Saren?
spk01: Thank you, Janet. We continue to see revenue improvement in 2022. and our revenue base continues to return to the core track feed pharmaceutical market platform. Our nationwide footprint continues to grow as we relentlessly focus on exciting new ways to support our large growing network of registered users, developing technology and products that better enable them to service their respective customers, the end users. strengthening their loyalty to their local retail pharmacy. Before we do a more detailed walkthrough of financial and operational results of the quarter, for those of you who are new to the company, I'd like to walk you through who we are and how we are digitalizing the retail pharmacy experience for the optimization of drug procurement, the prescription journey, and patient engagement. Prior to the launch of TraxAid, Obtaining drug codes as an independent pharmacy was an extremely laborious and time inefficient process with no insight or transparency into fair market price or what others are paying for the same drug. Traditional wholesalers would provide unfavorable payment terms, slow delivery, and create a difficult conundrum for the approximate 19,400 independent pharmacies nationwide. We identified this market inefficiency as well as incredible potential in these independent pharmacies, which together maintain an estimated approximately 67.1 billion in the annual purchasing power and proceeded to launch TracSafe. We designed, own, and operate a business-to-business, web-based market platform, bringing together the nation's independent pharmacies with accredited national pharmaceutical suppliers to provide a uniquely efficient and transparent buying and selling process. Our platform lets independent pharmacies know that they are receiving a fair price from competing suppliers and a fair payment terms and often with next day delivery. We believe this radical price transparency, economy of scale, and competition among suppliers leads up to a 10% reduction in a pharmacy's total annual drug purchase costs with a drug level savings of up to 90% on some certain pharmaceutical products. Our platform saves pharmacies from having to manually compare prices across distributors, saving hundreds of hours of unnecessary labor annually and eliminating negative reimbursements or fulfilling a prescription at a loss. Our revenue model is simple. We're paying an administrative fee of up to 6% of the buying price on a generic pharmaceutical and up to 1% on branded pharmaceuticals that pass through our pharmaceutical platform similar to PayPal or Visa-like model. To date, we've seen incredible success in garnering attention from these independent pharmacies nationwide validating our business model. Our TracSafe platform currently has over 13,815 registered members. New registered members in 2022 represent approximately 658 new members in the first half of 2022, with 339 new members added in the second quarter of 2022 itself. This is compared to 198 for the second quarter of 2021, and 420 for the first half of 2021. Another exciting growth metric on our TrackSafe platform includes a 21% increase in sales volume processed across our platform in the second quarter of 2022 compared to the same quarter of 2021. Our TrackSafe platform revenue also increased 11% in the second quarter of 2022 compared to the second quarter of 2021. Tract Shared Prime has also experienced exciting growth in the quarter. Comparing the second quarter of 2022 to 2021 reflects a 1.4 million increase in revenue and increases in the number of orders processed by approximately 330%. Tract Shared Prime also reflected a 713% increase in the number of units sold for the second quarter of 2022, compared to the same quarter in 2021. We expect this growth to continue in 2022. TraxAid Prime also announced a preferred distribution agreement with the Galt Pharmaceutical in July of 2022. The agreement with Galt adds single source and multi-source products to the TraxAid Prime catalog directly the manufacturer of Galt Pharmaceuticals. The partnerships add to the mission of helping our independent pharmacies and their members access top medication products as a part of the TractSafe Health Network. The partnership with the Gold Pharmaceutical will diversify our product offering, renews our commitment to our independent pharmacies. On the capital markets front, we continue to be initiative-taking. I presented at the Maxim Virtual Growth Conference on the panel Technology Improving Healthcare held on March 30th. I also attended the LD microinvitational held June 7th through June 9th. We attended conferences with the goal of enhancing broader investor awareness for our company. I'd like to now turn the call over to our Chief Financial Officer Janet Huffman to walk through some key financial highlights from the second quarter of 2022. Janet Huffman Thank you, Saran.
spk04: Let's discuss second quarter 2022 results. Revenues for the second quarter of 2022 increased 73% to $3.3 million, compared to revenue of $1.9 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by our TruxAid platform and TruxAid Prime. Due to increased revenues generated by the TrekSave platform and TrekSave Prime, growth profit increased to 1.2 million in the second quarter of 2022, compared to 800,000 for the same period in 2021. As a percent of revenue, our growth profit decreased to 36% in the second quarter of 2022, as compared to 44% in the second quarter of 2021. Operating expenses in the second quarter of 2022 were 2.3 million compared to 3.4 million in the same quarter last year. The expense decrease for these comparable periods is primarily due to a $1.2 million loss on inventory investment recognized in 2021, significantly increasing operating expenses for 2021 as compared to 2022. Net loss in the second quarter of 2022 was 1.1 million or 0.13 per basic and diluted share outstanding compared to 2.6 million or 0.32 per basic and diluted share outstanding for the same quarter in 2021. Adjusted EBITDA, a non-GAAP financial measure, was a negative 1.1 million for the quarter ended June 30th, 2022, compared to negative 1.2 million in the same quarter last year. Looking at our balance sheet, cash and cash equivalents were 1 million as of June 30th, 2022, compared with 3.1 million as of December 31st, 2021. A decrease in cash was mainly due to our IT initiatives our investment in SOSRX, increased salaries and wages, legal expenses, and other administrative expenses, as well as a cash prepayment for inventory that will fulfill a sales order in the third quarter of 2022. With that, I will turn the call back to Sarin for closing remarks.
spk01: Thank you, Janet. we're focusing on exciting new strategic partnerships to drive forward our core business, which is our marketplace, while diversifying our revenue base. Taken as a whole, I think we're building an incredible, compelling healthcare ecosystem, allowing consumers access to affordable healthcare by building an exciting value proposition for all stakeholders. I look forward to seeing what the future holds as we continue our rapid pace of operational execution, creating sustainable long-term value for my fellow shareholders. With that, I'll turn it over to the operator to begin the question and answer session.
spk02: Operator?
spk03: Thank you, sir. We will now begin the question and answer session. As a reminder, if you have a question, please press the star followed by the one on your touchtone phone. If you'd like to withdraw your question, press the star followed by the two. And if you are using speaker equipment, you will need to lift the handset before making your selection.
spk02: All right.
spk03: And our first question comes from the line of Alan Klee with Maxim Group. Please proceed with your question.
spk00: Good afternoon. Can you give us a sense of how you do you think that will have sequential revenue growth for each quarter for the rest of 22?
spk01: First of all, thank you, Alan, we still continues to see some issues in the supply chain, as well as the expenses in the transportation charges. That's towards an expensive so towards the revenue, we see A little bit of sequential growth, but we feel confident that we'll be having a sequential growth in the next two quarters, yes.
spk00: Great. And then in terms of your gross margins, they were hit a little bit with, I believe, due to Traxade Prime expanding. Do you believe that over the rest of the year that the gross margin should stay at the level they're at now or should improve or how should we think about that?
spk01: Janet, do you want to take that question?
spk04: Sure. Not a problem. You're right. The gross margin from a dollar perspective increased from a percent of revenue did decrease because there are the COGS on the platform side, there are not, right? And so when we grow the IPS revenue, we will see increased COGS as well. We've made some adjustments there, and I think that we will see some sustained growth margin as we move through the last two quarters of the year. Yep.
spk02: Okay.
spk00: Any update on your SOSRX partnership and also on the general purpose, the GPOs that you're working on?
spk01: Yeah. The SOSRX, as we are aware, our partnership just started. We signed that deal back in February. It took us a couple of months to even pitching the technology to the manufacturer. So we probably won't see any revenues for the rest of the year. Hopefully, probably the first quarter of next year, we will try to see some revenues. As far as the GPOs are concerned, we'll continue to add more members. That's what you see, the membership growth. I think, as mentioned earlier, the first quarter, the second quarter itself, 339 overall, 650. plus members that we've added in the first six months. So that's where you see a lot of the GPO pharmacies are joining our platform.
spk00: Thank you. I'll jump back in the queue.
spk03: And as a quick reminder, if anyone has any questions, you may press star 1 on the telephone keypad. Our next question goes to the line of Howard Halpert with AgriBrothers. Please proceed with your questions.
spk05: Good afternoon, guys. Good afternoon, Howard. If you could provide maybe a little bit more color on, you know, the recently announced agreement with Galt. And are you seeking other products with Galt or other pharmacies to do that kind of distribution? And what kind of business opportunity is there for that personalized, I guess, distribution?
spk01: Our main product or our main customer base is independent pharmacies, right? So we're trying to bring a manufacturer access to these specialty drugs that independent pharmacies don't have. So those relationships will give them the access to the drug in the first place and then higher margin that they can get from the reimbursements. So that's the reason it's bringing the manufacturer direct versus going through a big wholesale chain or wholesalers.
spk05: That they can lose the margin and we're trying to bring the manufacturer direct to my independent pharmacies Okay, and Just in terms of Operating expenses are we going to see that? I guess improve a little bit as you know as time goes by with some cost cutting measures or Are we in that $2.2 million range for the foreseeable future?
spk01: As you were, all the industries are facing some of the inflation issues, so we have to take care of our employees by increasing their salaries. Otherwise, we get threatened by their leaving and stuff. So I probably see that next two to three quarters sustainable at that level, $2.3 million level. probably in the 2023, we were able to see some improvements in those expenses. Okay.
spk05: And just one additional question. With the prime offering growing fairly rapidly, you know, and you talked about how the gross margin is, but do you have to add in any operating expenses or you know, as Prime grows? Or if Prime grows, your operating expenses for that are really relatively fixed?
spk01: That's an excellent question, Howard. Except shipping charges, I think we want to go after our electronic because we are focusing on the technology platform. So we would like to try to do the drop shipment directly from the DCs to where the customer base is instead of rebating the shipping costs so going forward we try to see sustainable expenses and accept the product cost we should see the higher margin on there also okay okay guys keep up the good work thank you and our next question comes from the line of alan clee with maximum group please proceed with your questions
spk00: Hi, just just in terms of your. In terms of the volumes that you're doing of sales through the tracks aid platform, can you give any commentary on if there are any changes in the mix of generic like the percent that generic says of the total mix?
spk01: Yeah, that's another one, Alan. I think as the supply chain issues globally are still pushing the pressure on the branded drugs that are available locally here, most of the generic products come from either India or other parts of the world. So we see the same trend, I hope, next six months to 15 months. We see the same trend, more of a brand versus less generic that are flowing through our platform.
spk02: Okay, thank you. And we have reached the end of the question and answer session. I'll now turn the call back over to Sirin for any closing remarks.
spk01: Thank you, operator. I'd also like to thank you, all of you, for joining our earnings conference call. We look forward to continuing to update you on the ongoing progress and growth. If we were unable to answer any of your questions, please reach out to our investor relations department who would be more than happy to assist. For any of you who may have joined the call in progress, remember that the replay of this call and a webcast will be available for the next 30 days on the company's website under the NASDAQ colon MEDS link, and that more information regarding the financial disclosed on this call and webcast during a reconciliation of non-GAAP financial information can be found in our press release, which we filed after the close of the market today. Thank you all.
spk03: And this concludes today's conference, and you may disconnect your lines at this time. Thank you and have a great day.
Disclaimer